A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
Phase: PHASE1 | Sponsor: MycoMedica Life Sciences PBC | Compound: Psilocybin
- Status
- recruiting
- Institution
- MycoMedica Life Sciences PBC
- Start date
- 2025-07-28
- End date
- 2026-02-01
- Registry ID
- NCT07050368
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.